Consistent use injectable and oral chondroprotectors in patients with osteoarthritis and lower back pain. Case report
| Autor: | Olga A. Shavlovskaya, Igor D. Romanov, Irina A. Bokova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Consilium Medicum, Vol 26, Iss 11, Pp 782-787 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2075-1753 2542-2170 20751753 |
| DOI: | 10.26442/20751753.2024.11.203037 |
| Popis: | Osteoarthritis (OA) is a disease of the entire joint, including structural changes in hyaline articular cartilage, subchondral bone, ligaments, capsule, synovial membrane and periarticular muscles. One of the causes of the development of nonspecific chronic lower back pain (LBP) is OA of the facet joints. In the treatment of OA and LBP against the background of OA facet joints, the chondroprotective agents are widely used: chondroitin sulfate (CS), glucosamine sulfate, undenatured type II collagen and their combinations. The aim of the article is to systematize the possibilities of practical application of Chondroguard TRIO® in patients with OA of different phenotypes and different localization. The experience of sequential administration of CS in patients (n=11) with OA and LBP with comorbid diseases is presented. At the initial stage of therapy, CS (Chondroguard®) was prescribed intramuscularly according to the scheme, then CS was prescribed perorally as part of a pharmaconutraceutical (Chondroguard® TRIO). The original pharmaconutraceutical Chondroguard® TRIO contains recommended doses of CS (1200 mg), glucosamine sulfate (1500 mg), undenatured type II collagen (40 mg). Clinical cases of the use of sequential administration of chondroprotectors (stage 1 – intramuscularly Chondroguard®, stage 2 – perorally Chondroguard® TRIO) demonstrate the clinical effectiveness of the proposed treatment regimen in patients of different age groups and OA phenotypes (posttraumatic, metabolic). |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|